Drug Combination Details
| General Information of the Combination (ID: C93197) | |||||
|---|---|---|---|---|---|
| Name | Genistein NP Info | + | Topotecan Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Genistein-topotecan combination was significantly more efficacious in reducing LNCaP cell viability compared with either genistein or topotecan alone. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Anticancer activities of genistein-topotecan combination in prostate cancer cells. J Cell Mol Med. 2012 Nov;16(11):2631-6. | |||
